A subset of breast cancer patients most likely to benefit from neoadjuvant regimen with Pan-HER inhibitor neratinib

I-SPY 2 study mechanism efficiently evaluates agents in biomarker-defined patient subsets. In a modest number of patients, its adaptive randomisation strategy successfully identified a biomarker signature for further development of pan-HER inhibitor, neratinib. A neoadjuvant regimen of standard chemotherapy and neratinib was beneficial for hormone receptor (HR)-negative, HER2-positive patients with primary breast cancer, according to data presented at the AACR Annual Meeting 2014 (5-9 April, San Diego, USA). Read more here.